Immunomodulatory Effects of Exercise in Experimental Multiple Sclerosis.
T cell
Theiler's virus-induced demyelinating disease (TMEV-IDD)
astroglia
cuprizone (CPZ)
experimental autoimmune encephalomyelitis (EAE)
lysolecithin (LPC)
microglia
rehabilitation
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2019
2019
Historique:
received:
31
07
2019
accepted:
30
08
2019
entrez:
2
10
2019
pubmed:
2
10
2019
medline:
21
10
2020
Statut:
epublish
Résumé
Multiple Sclerosis (MS) is a demyelinating and neurodegenerative disease. Though a specific antigen has not been identified, it is widely accepted that MS is an autoimmune disorder characterized by myelin-directed immune attack. Pharmacological treatments for MS are based on immunomodulatory or immunosuppressant drugs, designed to attenuate or dampen the immune reaction, to improve neurological functions. Recently, rehabilitation has gained increasing attention in the scientific community dealing with MS. Engagement of people with MS in exercise programs has been associated with a number of functional improvements in mobility, balance, and motor coordination. Moreover, several studies indicate the effectiveness of exercise against fatigue and mood disorders that are frequently associated with the disease. However, whether exercise acts like an immunomodulatory therapy is still an unresolved question. A good tool to address this issue is provided by the study of the immunomodulatory effects of exercise in an animal model of MS, including the experimental autoimmune encephalomyelitis (EAE), the Theiler's virus induced-demyelinating disease (TMEV-IDD) and toxic-demyelinating models, cuprizone (CPZ), and lysolecithin (LPC). So far, despite the availability of different animal models, most of the pre-clinical data have been gained in EAE and to a lesser extent in CPZ and LPC. These studies have highlighted beneficial effects of exercise, suggesting the modulation of both the innate and the adaptive immune response in the peripheral blood as well as in the brain. In the present paper, starting from the biological differences among MS animal models in terms of immune system involvement, we revise the literature regarding the effects of exercise in EAE, CPZ, and LPC, and critically highlight the advantages of either model, including the so-far unexplored TMEV-IDD, to address the immune effects of exercise in MS.
Identifiants
pubmed: 31572399
doi: 10.3389/fimmu.2019.02197
pmc: PMC6753861
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2197Informations de copyright
Copyright © 2019 Gentile, Musella, De Vito, Rizzo, Fresegna, Bullitta, Vanni, Guadalupi, Stampanoni Bassi, Buttari, Centonze and Mandolesi.
Références
Phys Ther. 2007 May;87(5):545-55
pubmed: 17405806
Autoimmun Rev. 2016 Sep;15(9):896-9
pubmed: 27396817
Cell Rep. 2018 Sep 18;24(12):3167-3179
pubmed: 30232000
Trends Cogn Sci. 2013 Oct;17(10):525-44
pubmed: 24029446
J Appl Physiol (1985). 1994 Nov;77(5):2341-7
pubmed: 7868453
Neuropharmacology. 2019 Feb;145(Pt A):75-86
pubmed: 29402503
Front Neurol. 2018 Nov 20;9:950
pubmed: 30524355
JAMA. 2005 May 25;293(20):2496-500
pubmed: 15914750
J Psychosom Res. 2014 Jun;76(6):465-71
pubmed: 24840141
Curr Protoc Mouse Biol. 2015 Dec 02;5(4):283-290
pubmed: 26629772
Acta Neuropathol. 2017 Feb;133(2):223-244
pubmed: 27766432
Mult Scler. 2016 Aug;22(2 Suppl):34-46
pubmed: 27465614
Mult Scler Relat Disord. 2018 Apr;21:24-29
pubmed: 29454153
Nat Rev Immunol. 2015 Sep 15;15(9):545-58
pubmed: 26250739
Ann Clin Transl Neurol. 2019 Sep;6(9):1647-1658
pubmed: 31368247
Nat Rev Neurol. 2019 Jan;15(1):53-58
pubmed: 30315270
J Neurosci Res. 2016 Oct;94(10):907-14
pubmed: 27312674
Neurosci Lett. 2018 Oct 15;685:150-154
pubmed: 30171909
Int J Sports Med. 2018 Jul;39(8):604-612
pubmed: 29775986
Brain. 2007 Apr;130(Pt 4):1089-104
pubmed: 17438020
Eur J Appl Physiol Occup Physiol. 1996;73(1-2):130-5
pubmed: 8861681
Lab Anim (NY). 2016 May 20;45(6):213-5
pubmed: 27203261
Brain Pathol. 2001 Jan;11(1):107-16
pubmed: 11145196
J Neurosci Res. 2015 May;93(5):697-706
pubmed: 25510644
Neuroscience. 2017 Mar 27;346:173-181
pubmed: 28108255
Eur J Pharmacol. 2015 Jul 15;759:182-91
pubmed: 25823807
Mult Scler. 2014 Mar;20(3):382-90
pubmed: 24158978
J Neurosci Methods. 2016 Nov 1;273:191-200
pubmed: 27498037
J Neuroimmunol. 2019 Mar 15;328:60-67
pubmed: 30583216
J Virol. 1995 Apr;69(4):2525-33
pubmed: 7884902
J Immunol. 1994 Jan 15;152(2):919-29
pubmed: 7506740
Brain Behav Immun. 2018 Mar;69:235-254
pubmed: 29175168
Appl Physiol Nutr Metab. 2013 Feb;38(2):194-9
pubmed: 23438232
Chem Phys Lipids. 2017 Oct;207(Pt B):127-134
pubmed: 28606714
Nat Rev Neurol. 2015 Dec;11(12):711-24
pubmed: 26585978
Behav Neurosci. 2015 Aug;129(4):457-72
pubmed: 26052795
Ann Neurol. 2000 Jun;47(6):707-17
pubmed: 10852536
Neurobiol Dis. 2009 Oct;36(1):51-9
pubmed: 19591937
Physiol Res. 2015;64(6):907-23
pubmed: 26047382
Brain Behav Immun. 2019 Jan;75:137-148
pubmed: 30287389
J Neuroimmunol. 2017 Apr 15;305:135-144
pubmed: 28284334
J Neurol Sci. 2004 Oct 15;225(1-2):11-8
pubmed: 15465080
Am J Pathol. 2003 Apr;162(4):1259-69
pubmed: 12651618
Neurobiol Dis. 2019 Sep;129:102-117
pubmed: 31100354
Mol Neurobiol. 2017 Aug;54(6):4723-4737
pubmed: 27447807
Eur J Neurosci. 2007 Feb;25(3):761-71
pubmed: 17298600
J Appl Physiol (1985). 2007 Dec;103(6):1979-85
pubmed: 17916671
Neurotox Res. 2013 Aug;24(2):244-50
pubmed: 23392957
Lancet Neurol. 2017 Oct;16(10):848-856
pubmed: 28920890
J Neurochem. 2016 Jan;136 Suppl 1:63-73
pubmed: 26364732
J Neuroimmunol. 2013 Nov 15;264(1-2):24-34
pubmed: 24054000
Ann Neurol. 2003 May;53(5):680-4
pubmed: 12731006
Lancet. 2017 Apr 1;389(10076):1357-1366
pubmed: 27889191
Exp Neurol. 2018 Jan;299(Pt A):56-64
pubmed: 29031957
Exp Neurol. 2015 Sep;271:279-90
pubmed: 26033473
J Neuroimmunol. 2014 Sep 15;274(1-2):14-9
pubmed: 24999244